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Brief Clinical ReportsFirst experience with a paracorporeal artificial lung in a small child
with pulmonary hypertensionAvihu Z. Gazit, MD,a Stuart C. Sweet, MD,b R. Mark Grady, MD,c and Charles B. Huddleston, MD,d
St Louis, MoStabilizing children with decompensating refractory pul-
monary hypertension may require extracorporeal circula-
tory support. Currently, options in this regard are limited
to use of venoarterial extracorporeal membrane oxygena-
tion (ECMO), but this approach is frequently fraught with
complications. Alternatively, the interventional pumpless
lung-assist membrane ventilator (Novalung GmbH, Heil-
bronn, Germany) can be used through a femoral artery to
femoral vein shunt in patients with end-stage lung disease
and hypercapnia or hypoxemia refractory to mechanical
ventilation and through a pulmonary artery to left atrium
shunt in patients with refractory pulmonary hypertension.
The latter configuration has several advantages for children
with pulmonary hypertension: (1) It provides a parallel low
resistance circuit that drastically decreases right ventricular
(RV) afterload and native pulmonary pressure, allowing RV
recovery and pulmonary vascular remodeling. (2) It may
serve as a long-term pulmonary assist device or as a bridge
to lung transplant or a bridge to recovery. (3) It allows phys-
ical rehabilitation. Here we report the first successful use of
the Novalung surgical lung-assist (sLA) device in a small
child with pulmonary hypertension.CLINICAL SUMMARY
A 2-year-old boy (13.6 kg, body surface area 0.62 m2)
was seen in extremis after a 3-month history of anorexia, in-
termittent diarrhea, and rash. He was transported to our hos-
pital after tracheal intubation, initiation of mechanical
ventilation, and inotropic support. A diagnosis of pulmo-
nary hypertension was made with transthoracic echocardi-
ography, prompting administration of inhaled nitric oxide
(Table 1). On day 2, venoarterial (right internal jugularFrom the Divisions of Critical Care and Cardiology, Department of Pediatrics,a the
Division of Allergy, Immunology, and Pulmonary Medicine, Department of Pedia-
trics,b the Division of Cardiology, Department of Pediatrics,c and the Division of
Pediatric Cardiothoracic Surgery, Department of Surgery,d Saint Louis Children’s
Hospital, Washington University in Saint Louis, Missouri, St Louis, Mo.
Disclosures: Authors have nothing to disclose with regard to commercial support.
Received for publication Nov 15, 2010; revisions received Jan 6, 2011; accepted for
publication Feb 9, 2011; available ahead of print Mach 21, 2011.
Address for reprints: Avihu Z. Gazit, MD, Divisions of Critical Care and Cardiology,
Department of Pediatrics, Saint Louis Children’s Hospital, Washington University
in Saint Louis, One Children’s Place, Northwest Tower, 8th floor, St Louis, MO
63110 (E-mail: gazit_a@kids.wustl.edu).
J Thorac Cardiovasc Surg 2011;141:e48-50
0022-5223/$36.00
Copyright  2011 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2011.02.005
e48 The Journal of Thoracic and Cardiovascular Surgvein–right carotid artery) ECMO support was initiated be-
cause of (1) worsening hypoxemia related to shunting
across the atrial septum (oxygen saturation 75%–82%,
PaO2 43–51 mm Hg, inhaled nitric oxide 40 ppm, inspired
oxygen fraction 1), (2) severely decreased right ventricular
(RV) systolic function consequent to suprasystemic pulmo-
nary pressures (echocardiographic estimate of RV pressure
was 88 mm Hg with right atrial V wave, systolic femoral
arterial blood pressure was 81 mm Hg), and (3) severe
metabolic acidosis (pH 7.23, PaCO2 38 mm Hg, base excess
11.2), despite escalating inotropes (epinephrine 0.08 mg/
[kg $ min], dopamine 15 mg/[kg $ min], milrinone 0.5 mg/
[kg $ min]). During the period of ECMO support (17
days), the patient was listed for lung transplant. Because
we expected a prolonged ECMO course before transplanta-
tion, with an anticipated survival of only 40% for children
with idiopathic pulmonary arterial hypertension supported
with ECMO according to our experience and data obtained
from the ECMO Registry of the Extracorporeal Life Sup-
port Organization (ELSO),1 we decided to transition our pa-
tient to paracorporeal Novalung sLA support. As stipulated
in the Food and Drug Administration’s Guidance for Com-
passionate Use, we reviewed the case with the Washington
University School of Medicine human research protection
office and discussed the risks and benefits of the Novalung
sLA device at length with this patient’s parents, who agreed
to proceed with this plan.
Novalung sLA device implantation was performed while
the patient was attached to ECMO. The sLA device was
interposed in a shunt created between the main pulmonary
artery and the left atrium. As expected, the low-resistance
oxygenator circuit acutely decreased RV afterload and
achieved normal gas exchange while bypassing the native,
high-impedance, pulmonary vasculature, allowing separa-
tion from ECMO immediately after establishment of the
sLA shunt. To create the shunt, 12 3 9-mm arterial Berlin
heart cannula (Berlin Heart AG, Berlin, Germany) was
sewn to the pulmonary artery in an end-to-side fashion,
and a 22F DLP right-angle single-stage venous cannula
(DLP Medtronic, Inc, Grand Rapids, Mich) was placed in
the left atrium. ATransonic HT110 bypass flowmeter (Tran-
sonic Systems, Inc, Ithaca, NY) and a 3/8 -inch flow probe
were used to monitor Novalung sLA device flow. A Sechrist
3500 low-flow air–oxygen mixer (Sechrist Industries, Inc,
Anaheim, Calif) was used to control Novalung gas flow
and inspired oxygen fraction. Medical therapy forery c June 2011
TABLE 1. Pulmonary vasodilator therapy and significant interventions during the child’s hospitalization
Date iNO dose Sildenafil dose Bosentan dose Flolan dose Significant event
June 11, 2010 40 ppm
June 12, 2010 20 ppm ECMO cannulation
June 14, 2010 30 ppm
June 15, 2010 20 ppm
June 29, 2010 Stop Novalung* placement
June 30, 2010 20 ppm
July 3, 2010 20 ppm 4.5 mg QID
July 6, 2010 20 ppm (nasal cannula) Extubation
July 12, 2010 20 ppm (nasal cannula) 6.0 mg QID 6 ng/(kg $ min)
July 13, 2010 20 ppm (nasal cannula) 9 ng/(kg $ min)
July 22, 2010 Stop Novalung* removal
July 23, 2010 31.25 mg BID 20 ng/(kg $ min)
July 24, 2010 21 ng/(kg $ min)
Aug 11, 2010 10 mg TID 27 ng/(kg $ min)
Aug 23, 2010 29 ng/(kg $ min)
iNO, Inhaled nitric oxide; ECMO, extracorporeal membrane oxygenation; QID, 4 times daily; BID, 2 times daily; TID, 3 times daily. *Novalung surgical lung-assist device;
Novalung GmbH, Heilbronn, Germany.
Brief Clinical Reportspulmonary hypertension was escalated further during Nova-
lung support (Table 1). Device flow remained stable during
the course of the first 14 days after its placement (1.978 
0.03–2.28  0.02 L/min) and then diminished gradually
before device removal, reaching a new baseline
(1.872  0.03–1.609  0.03 L/min; Figure 1). Initial PaO2
and PaCO2 after device placement were 331 mm Hg and
39 mm Hg, respectively. On day 26, the patient was extu-
bated and allowed to mobilize in bed (Figure 2). Anticoagu-
lation was maintained with heparin infusion (target
activated clotting time 160–200 seconds); however, peri-
odic circuit changes were required because of clot forma-
tion. On day 42, after 17 days of ECMO and 23 days of
Novalung support, our patient had an acute embolic stroke
in the left middle cerebral artery distribution. The sLA de-
vice was removed later that day. The stroke was acutely
manifested by dense hemiparesis and aphasia; both findings
were nearly resolved by discharge. Three months after the
original presentation, the patient was discharged home
treated with continuous infusion of epoprostanol (Flolan;
Table 1). An echocardiographic estimate of the RV pressure
6 months after initial presentation was 51 mmHg with right
atrial V wave.FIGURE 1. Hourly Novalung (Novalung GmbH, Heilbronn, Germany)
surgical lung-assist device flow readings presented as mean  SEM. Day
1 is the day of Novalung placement and day 24 is the day of the device re-
moval. Note the decrease in baseline flow rates occurring around day 14.DISCUSSION
Currently, ECMO provides the only viable support for
children with life-threatening cardiopulmonary failure as-
sociated with idiopathic pulmonary arterial hypertension.
To assess the outcome of children with idiopathic pulmo-
nary arterial hypertension (International Classification of
Diseases, 9th Revision, Clinical Modification diagnosis
code 416.0) supported with ECMO, we queried the ELSO
registry database1 for children between the ages of 1 month
and 18 years from January 1986 to July 2010. A total of 48The Journal of Thoracic and Cachildren carrying this diagnosis were placed on ECMO sup-
port during that period, with a median duration of support of
7 days (range, 3 hours–39 days). Of those children, 19 sur-
vived (40%), and multiple complications were reported.1
These data are supported by a recent review of our institu-
tional lung transplant database,2 which revealed that the
need for perioperative ECMO support is associated with
significant morbidity and mortality in the pediatric lung
transplant population. Our data also notably indicated that
the waiting period for suitable donor organ availability is
rarely shorter than 39 days,2 the longest period of successful
ECMO support for pulmonary hypertension reported in the
ELSO registry.1 A pumpless, low-resistance artificial lung
may expose the patient to fewer complications associated
with consumption of coagulation factors or hemolysis.rdiovascular Surgery c Volume 141, Number 6 e49
FIGURE 2. The patient is extubated and allowed to mobilize in bed.
Brief Clinical ReportsThe parallel, low-resistance, RV to left atrium shunt signifi-
cantly reduces RVafterload and vascular wall stress during
pulmonary vasodilator therapy. On the basis of studies in
animals and in patients with congenital heart disease,
as well as our own experience in children with heart fail-
ure–related pulmonary hypertension supported with
a biventricular assist device (Berlin Heart VAD), we have
concluded that pulmonary vasodilator therapy combined
with extracorporeal or paracorporeal decompression of
the pulmonary vascular bed facilitates reverse remodeling
and response to therapy in severely advanced pulmonary
hypertension.3,4 We speculate that by lessening wall stress
such hemodynamic unloading5 confers benefit by dampen-
ing the pathologic signaling that maintains increased pul-
monary vascular tone and hypertrophy. The stroke that
our patient had was indeed a major complication; however,
this event appears to have been reasonably tolerated, is re-
solving, and does not preclude our patient’s candidacy for
lung transplantation. The unique combination of Novalung
sLA support and aggressive pulmonary vasodilator therapy
permitted an entirely unexpected outcome: discharge home
with no immediate need for lung transplant. Our patient’s
clinical improvement highlights the need for a controllede50 The Journal of Thoracic and Cardiovascular Surgtrial of this device in children with pulmonary failure
related to different etiologies in the pediatric population.
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